RoC Skincare® Champions Empowered Aging with New Brand Initiative
Leading Clinically-Proven Skincare Brand Launches New Research, Longevity Council, Brown University Research Fund, and continued SeekHer Foundation Community Efforts
NEW YORK, May 21, 2025 /PRNewswire/ -- RoC Skincare® today announces its expanded commitment to empowered aging and supporting the long-term health and vitality of skin. Offering new research about aging perceptions, expert-backed education, advanced clinically-proven skincare technology, and philanthropic efforts, RoC launches its Empowered Aging initiative.Building upon the work RoC established with its Look Forward Project, which spotlighted the benefits of incorporating optimism for longevity, the new initiative offers additional functional, educational and emotional resources to support women's inner and outer vitality. Included in these efforts are the introduction of the RoC Longevity Council, initiation of a research fund to benefit the Center on the Biology of Aging at Brown University, and a continuation of its women's mental health advocacy partnership with the SeekHer Foundation."Optimism and clinically-proven efficacy have been at the core of our brand ethos for years, and these new efforts further our commitment to supporting women through their aging journey," said Hillary Hutcheson, Chief Marketing Officer at RoC Skincare. "Our Empowered Aging initiative equips women at every stage of life with resources to make smarter, proactive choices that can impact longevity and skin health as we get older."New Research on Aging Perceptions & Skincare Product Efficacy For more than six decades, RoC Skincare has been dedicated to empowering women with clinically proven products that enhance skin health and appearance, including its best-selling Line Smoothing Eye Cream. Inspired by the insight that a significant 70% of women report feeling younger than their actual age1, RoC delved further and found that 81% of women feel like the appearance of their skin impacts how they feel emotionally2. With that in mind, RoC conducted a unique study to explore if its popular eye cream could help narrow the gap between women's skin age and the age they feel.In collaboration with a board-certified dermatologist, RoC enlisted eight women to participate in an in-depth study utilizing Visia® Skin imaging to assess changes in apparent eye age after 8 weeks of consistent use of RoC's Line Smoothing Eye Cream. The results demonstrated that 100% of participants experienced an improvement, with some seeing a decrease of up to 7 years in apparent eye age, better aligning their outer appearance with their inner sense of vitality and inspiring optimism about the future. This clinically measured improvement is attributed to RoC Retinol, a potent yet gentle time-released ingredient backed by 27 years of research and 35 patents, delivering continuous results for up to 12 hours. To share the compelling experiences of these women, RoC has launched a new holistic campaign that examines the impact of under-eye appearance on self-perception and perceived age, highlighting the eyes as a key indicator of vitality.
To bring the study to life and in celebration of the launch of its Empowered Aging initiative, RoC Skincare will host a pop-up experience in New York City on June 11-13. Attendees have the opportunity to determine their own True Eye Age with the Visia® Skin Analysis utilized in the study, speak with a dermatologist about their specific eye concerns, receive complimentary full-sized Line Smoothing Eye Cream samples3, win prizes3, and more.
Longevity Council
As the brand expands into a more holistic approach to longevity and well-being, its new Longevity Council will help shape RoC's long-term vision for empowered aging, driving research, community events, and thought leadership in the field. This group of specialists represents a diverse range of aging-related disciplines, from biochemistry to physical health and general wellness, and will serve as key resources, providing education and counsel on new innovation from RoC to support skin longevity. Members include:
Allie Egan, Founder of Veracity
Chris Mirabile, Founder & CEO of NOVOS and Member of the Longevity Biotechnology Association
Florence Comite MD, CEO & Founder Comite Center for Precision Medicine & Healthy Longevity
Dr. Jeanine Downie, MD, Board Certified Dermatology, Image Dermatology PC
Professor John M Sedivy, PhD, Director of the Brown University Center on the Biology of Aging
Yasmine Cheyenne, Self Healing Expert, Author, & Wellness Coach for Today Show's "Start Today"
Research Fund with Brown University
The establishment of the RoC Skincare Longevity Research Fund, gifted to Brown University Center on the Biology of Aging, will fuel groundbreaking research, pave the way for the development of innovative skincare solutions, and contribute valuable knowledge to the broader scientific community.
"We applaud RoC Skincare's vision of a holistic approach to healthy aging, whose goal is to empower all of us to reach our fullest potential," adds Professor John Sedivy, Longevity Council Member. "We are excited to partner with them on catalyzing research on the fundamental biological processes of aging."
Continued SeekHer Foundation Partnership
In a tangible community-based effort to empower women across the country, RoC continues its partnership with the SeekHer Foundation, a non-profit dedicated to women's mental health advocacy, research, and support, via its new Empowered Aging Support Program:
Empowered Aging Guide: Co-branded downloadable step-by-step resource to support women through their Empowered Aging journey
4-Part Virtual Heal & Lead Circles: Facilitated by licensed mental health experts, these themed sessions offer deeper exploration of topics on vibrant living, mindful aging, building strong connections, and finding purpose in their later years, fostering peer engagement
Ongoing Community Resource Access: Monthly reflection prompts centered on women's health and empowered aging, offering the community opportunities to connect, share insights, and offer mutual support
"This year-long initiative is an active commitment to transforming women's experience of aging with optimism and vitality," adds Monica Mo, founder and Executive Director of SeekHer Foundation and WellSeek. "RoC is helping us foster strong communities where shared well-being leads to meaningful personal growth and a stronger network of support for all."
Follow RoC Skincare on Instagram and TikTok @rocskincare to learn more about the Empowered Aging initiative and where NYC locals can visit the "Eyes First" Pop-up Truck.
About RoC Skincare
RoC Skincare has been revolutionizing skincare science since 1957 when Dr. Jean-Charles Lissarrague, a French pharmacist at the Rogé Cavaillès pharmacy, created the first hypoallergenic skincare formulations. RoC has continued to build on its legacy as a brand of firsts, launching the first broad-spectrum UV protection to proactively preserve the health of skin, and the first brand to discover the method for stabilizing Retinol. Collaborating closely with Dermatologists, RoC scientists have spent over 67 years garnering a deep understanding of skin physiology at the cellular level. Today, RoC is at the forefront of dermatological innovation, harnessing cutting-edge technology to achieve over 35 patented breakthroughs in Retinol, Vitamin C, Hyaluronic Acid and Pro Collagen Amino Acids. With over 150 clinical studies, every RoC formula undergoes rigorous clinical testing to prove its high efficacy without any compromises on safety. RoC is 100% hypoallergenic,100% non-comedogenic, PETA-approved, and always clinically proven.
Contact: M Booth at RoCSkincare@mbooth.com
1Study from the University of Virginia, USA on 30,000 subjects2RoC Perksy Study: US, April 20253while supplies last
View original content to download multimedia:https://www.prnewswire.com/news-releases/roc-skincare-champions-empowered-aging-with-new-brand-initiative-302462029.html
SOURCE RoC Skincare
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare
Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13, 2025 /PRNewswire/ -- The Berwyn Group (Berwyn), the leader in death audit, locate services and population management, is pleased to announce the hiring of Adam Wilson as General Manager of Healthcare. Wilson brings extensive healthcare industry experience that will further strengthen Berwyn's commitment to excellence and growth. Berwyn offers an end-to-end suite of industry-leading death audit and locate solutions that enable pension and health plan administrators to eliminate costly overpayments, maximize efficiency, meet regulatory requirements, and connect policyholders, participants and beneficiaries to the funds they deserve. More than 2,000 corporate, union and government clients use Berwyn's flagship services, CertiDeath® and CertiCensus®. Wilson joins Berwyn with a distinguished career that spans almost 17 years at UnitedHealthcare, where he held several leadership roles including Vice President of Workforce Planning, Chief of Staff to the COO, and Vice President of Medicare Part D products. "We are thrilled to welcome Adam to the team," said John Bikus, President of Berwyn. "His strategy, proven leadership, and deep industry knowledge will be invaluable as we continue to grow in the healthcare industry." In his new role, Wilson will be responsible for leading Berwyn's strategic expansion into the healthcare market. He will be focusing on aligning Berwyn's solutions to the healthcare payer and provider business cycle needs while also extending the Berwyn reach to healthcare-related supporting partners, vendors, and industry trade groups. "I'm eager to join an organization positioned for rapid growth through industry-leading capabilities," said Wilson. "I look forward to collaborating with the talented team at Berwyn to deliver quick wins, strategic expansion into healthcare, and contribute to the company's continued success." About The Berwyn Group The Berwyn Group is the leader in population data management, offering the industry's most trusted and effective death audit and locate solutions, with an unmatched dedication to innovation, security, and generating outcomes. Acquired by Longevity Holdings in 2023, The Berwyn Group offers an end-to-end suite of industry-leading solutions including CertiDeath® Paragon™, CertiDeath®, CertiCensus®, CertiSearch® and BeneSearch®. Connecting leading-edge technology and data with best-in-class human ingenuity, Berwyn helps bridge the gap between pensions and their participants, insurance companies and their policyholders, third-party administrators and public entities with Medicaid recipients. For more information, visit Media Contact Karlene Gilmore Director of Marketing kgilmore@ View original content: SOURCE The Berwyn Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio


Business Wire
a day ago
- Business Wire
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept. 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. For more information, visit